Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Adaptimmune Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2025 was $125.24M, down 14.6% year over year. For fiscal 2024 it was $149.06M, up 17.8% from the year before. The highest annual figure on record is $149.06M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $149.06M | +17.8% |
| FY2023 | Dec 31, 2023 | $126.51M | -1.0% |
| FY2022 | Dec 31, 2022 | $127.73M | +15.0% |
| FY2021 | Dec 31, 2021 | $111.09M | +21.3% |
| FY2020 | Dec 31, 2020 | $91.57M | -6.1% |
| FY2019 | Dec 31, 2019 | $97.50M | -0.8% |
| FY2018 | Dec 31, 2018 | $98.27M | +12.5% |
| FY2017 | Dec 31, 2017 | $87.39M | +262.0% |
| FY2015 | Jun 30, 2015 | $24.14M | +152.1% |
| FY2014 | Jun 30, 2014 | $9.58M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $22.98M | -43.2% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $28.86M | -18.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $39.10M | +17.7% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $34.30M | -9.2% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $40.45M | +35.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $35.21M | +37.8% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $33.21M | +44.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $37.79M | +13.9% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $29.97M | -13.7% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $25.55M | -30.5% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $23.05M | -21.9% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $33.18M | +17.6% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $34.74M | +20.3% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $36.75M | +50.0% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $29.51M | +14.5% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $28.21M | +17.2% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $28.87M | +41.1% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $24.51M | +15.2% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $25.78M | +26.6% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $24.07M | -18.7% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $20.46M | -19.8% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $21.26M | -3.4% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $20.35M | -10.6% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $29.62M | +26.1% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $25.51M | -4.2% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $22.02M | -14.4% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $22.77M | -9.5% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $23.48M | -2.3% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $26.62M | +35.9% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $25.73M | +38.2% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $25.15M | +199.2% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $24.03M | +302.2% |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $19.59M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $18.62M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $8.40M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $5.98M | – |
See a number that looks wrong?